RxDoctor Payments Data

Hari Deshpande, MD

Interventional Cardiology · New Haven, CTNPI 1447248117

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Daiichi Sankyo Inc. at 43.1% of the total. Reporting peaked in 2020 at $11,560 and has fallen 74.0% since, to $3,000 in 2025.

$23,403in general payments, 2019–2025

Across 29 payments — averaging $806.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$10K
  • Deciphera Pharmaceuticals Inc.$5K
  • Springworks Therapeutics, Inc.$3K
  • Aadi Bioscience, Inc.$3K
  • Exelixis Inc.$2K
  • Blueprint Medicines Corporation$950
$1,204,296in research payments, 2019–2025

Across 276 payments — averaging $4363.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Deciphera Pharmaceuticals Inc.$422K
  • Servier Bioinnovation$318K
  • PTC Therapeutics, Inc.$214K
  • Eisai Inc.$113K
  • Boehringer Ingelheim$52K
  • Karyopharm Therapeutics Inc.$45K
  • plus $41K from 4 others

What the payments were for

  • Consulting fees$13,06556%
  • Speaking & faculty fees$7,77533%
  • Travel & lodging$1,8788%
  • Food & beverage$6853%

General payments by program year

20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,403 in reported general payments places this provider in the 85th percentile of 73 interventional cardiology providers in Connecticut.

See all interventional cardiology providers in Connecticut

Medicare billing

Part B allowed, 2024
$73,525
Medicare patients
209
Services billed
600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LenvimaLenvatinib Mesylate58$1,252,939
CabometyxCabozantinib S-Malate22$499,484
RetevmoSelpercatinib14$152,616
Pazopanib Hcl31$144,458
Imatinib Mesylate35$103,028
EliquisApixaban16$9,515
XyostedTestosterone Enanthate12$8,499
Oxycodone Hcl124$5,091
Methadone Hcl17$1,305
Ondansetron OdtOndansetron39$843
Albuterol Sulfate HfaAlbuterol Sulfate12$483
Prochlorperazine Maleate29$479
Amitriptyline Hcl12$372
Levothyroxine Sodium16$319
Morphine Sulfate ErMorphine Sulfate12$260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$1,980$499,48422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 73 interventional cardiology providers in Connecticut.

Other interventional cardiology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →